Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

During his appearance on the " Armchair Expert " podcast on Monday, the "Frozen" actor opened up about taking weight loss ...

As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.